While using small molecule AMPK activators to treat a panel of human metabolic and neurodegenerative diseases now appears achievable, further investigations should be carried out before such activators, direct or indirect, reach the clinic for the treatment of myeloid malignancies. This evidence concerns the gene PRKAA1 and neurodegenerative disease.